www.ForMeFirst.com  
Universal Healthy Lifestyle
Roadmap to Long Happy Life
Since 1998

All Willing Souls Can Do It                   
And We Can Help
                  
Email: realinct2002@yahoo.com                   
Dr. Lin's Quest beyond Medication and Surgery                 
    Copyright is preserved. Copying is prohibited without author's permission.

    Latest Updates on Cryo Online Data Registry Outcomes: Minimum Five Year Follow up Data

    Authors: David Levy*, Euclid, OH, Christopher Williams, Jacksonville, FL, Thomas Polascik, Durham, NC, Stephen Jones, Cleveland,
    OH
    Abstract: MP45-16 in 2014 AUA Convention in Orlando, Florida

    Introduction and Objectives
    We report a comprehensive update of 5 year COLD Registry outcomes for patients undergoing primary whole gland prostate
    cryoablation.

    Methods
    A risk stratified cohort of 1,111 treatment naïve patients who underwent primary whole gland cryoablation was identified. 5 year
    biochemical progression free Kaplan Meier survival curves were constructed based on Phoenix definition.

    Results
  • Overall bPFS* was: 79.9%, 64.1% and 68.1%, low, intermediate and high risk, respectively, (Figure 1).

  • For 817 (73.5%) patients with nadir PSA < 0.4 ng/ml, bPFS* was 91%, 80.5%, and 77.6%, low, intermediate and high risk,
    respectively.

  • Patients with a nadir PSA > 0.4 ng/ml demonstrated 24-month biochemical progression rates in excess of 34%.

  • Continence was preserved in 93.4% of patients, while 5.9% of patients had retention and 0.5% developed a rectal fistula.

  • Potency data entered into the Registry data base revealed that 35% of patients were potent at 12 months.

    Conclusions
  • 5 year bPFS* following prostate cryoablation is comparable to surgical and radiation outcomes across all risk categories with a
    lower likelihood of procedure related complications.

  • A nadir PSA > 0.4 ng/ml predicts a high likelihood of biochemical progression and warrants close follow up.

                
* bPFS: biochemical progression free survival

    Date & Time: May 18, 2014 3:30 PM-5:30 PM
    Session Title: Prostate Cancer: Localized III
    Sources of Funding: none

    Abstracts printed from AUA2014.org
PSA / its Use, Prostate
Cancer / its Care...
www.ForMeFirst.com  
Universal Healthy Lifestyle
Roadmap to Long Happy Life
Since 1998